FDAnews
www.fdanews.com/articles/196752-bis-ofev-approved-in-europe-for-interstitial-lung-disease

BI’s OFEV Approved in Europe for Interstitial Lung Disease

April 22, 2020

The European Commission has approved Boehringer Ingelheim’s Ofev (nintedanib) for treatment of systemic sclerosis-associated interstitial lung disease.

The approval was based on results from a phase 3 clinical trial which showed that Ofev slowed the loss of pulmonary function in patients with the disease.

The FDA approved Ofev for systemic sclerosis-associated interstitial lung disease in September 2019.

View today's stories